Background:

Cefadroxil is a new semisynthetic cephalosporin with a broad antibacterial spectrum and a high chemotherapeutic potential [1].

In vitro: The inhibitory activity of this compound was similar to that of cephalexin and cephradine when tested against 602 clinical isolates on Mueller-Hinton medium. In the oral treatment of experimental infections of mice, cefadroxil was more effective than cephalexin against Streptococcus pyogenes, and comparably effective against Streptococcus pneumoniae, Staphylococcus aureus, and several gram-negative species [1].

In vivo: In mice, oral administration of cefadroxil at doses ranging from 25 to 100 mg/kg attained peak concentrations in the blood. Higher peak levels were noted with cefadroxil than with cephalexin at a dose of 200 mg/kg [1].

Clinical trials: A single daily dose of cefadroxil appeared to be as effective in the treatment of patients with A β-hemolytic streptococcal (GABHS) pharyngitis [2].

参考文献:
[1] Buck R E, Price K E.  Cefadroxil, a new broad-spectrum cephalosporin[J]. Antimicrobial agents and chemotherapy, 1977, 11(2): 324-330.
[2] Gerber M A, Randolph M F, Chanatry J, et al.  Once daily therapy for streptococcal pharyngitis with cefadroxil[J]. The Journal of pediatrics, 1986, 109(3): 531-537.